Autres langues Immunovia AB London S.E.

Actions

Marché Fermé - London S.E. Autres places de cotation 11:13:42 21/03/2024			Varia. 5j.	Varia. 1 janv.
1,4 ^SEK	-96,26%		-.--%	-22,82%

21/05	Immunovia recherche 70 millions de couronnes suédoises dans le cadre d'un projet d'offre de droits	MT
29/04	Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024

Immunovia : Convening notice 2024	21/05
Immunovia : Statement from nomination committee 2024	21/05
Immunovia : Remuneration report	21/05
Immunovia : Proposal for remuneration guidelines	21/05
Immunovia : Proposal for resolution on reduction of the share capital	21/05
Immunovia : Proposal for resolution on amendment of the Articles of Association	21/05
Immunovia : Resolution on rights issue of units subject to approval by the annual general meeting	21/05
Immunovia : Proposal for resolution to authorize the board of directors to issue shares and warrants to guarantors	21/05
Immunovia : Proposal for resolution on authorization of the board to resolve on new issue of shares	21/05
Immunovia Seeks SEK70 Million from Proposed Rights Offering	21/05
NOTICE OF ANNUAL GENERAL MEETING IN IMMUNOVIA AB (PUBL)	21/05
Immunovia carries out a rights issue of units of approximately SEK 70 million and raises bridge loans	20/05
Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director	29/04
Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina	29/04
Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina	29/04
Immunovia Appoints Lisa Ford as Clinical Laboratory Director	29/04
Immunovia publishes the annual report for 2023	29/04
Immunovia Publishes Interim Report for January-March 2024	29/04
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Invitation to Immunovia's Q1 presentation	23/04

Aucun résultat pour cette recherche